AssuredPartners Investment Advisors LLC Invests $478,000 in Becton, Dickinson and Company $BDX

AssuredPartners Investment Advisors LLC acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,553 shares of the medical instruments supplier’s stock, valued at approximately $478,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BDX. Saudi Central Bank purchased a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth approximately $26,000. Kelly Lawrence W & Associates Inc. CA bought a new position in Becton, Dickinson and Company in the first quarter worth approximately $31,000. Bell Investment Advisors Inc lifted its holdings in Becton, Dickinson and Company by 474.1% during the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 128 shares during the period. WPG Advisers LLC bought a new stake in Becton, Dickinson and Company during the 1st quarter valued at $36,000. Finally, Bank of Jackson Hole Trust increased its holdings in shares of Becton, Dickinson and Company by 85.6% in the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 95 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the sale, the director directly owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders sold 407 shares of company stock worth $73,922. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Trading Down 0.3%

Becton, Dickinson and Company stock opened at $200.37 on Tuesday. The stock has a 50-day moving average price of $189.07 and a 200 day moving average price of $184.85. The company has a market capitalization of $57.19 billion, a price-to-earnings ratio of 34.37, a price-to-earnings-growth ratio of 1.86 and a beta of 0.25. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The company had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Monday, December 8th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio is currently 72.04%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Argus raised their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Piper Sandler cut their price objective on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Finally, Royal Bank Of Canada decreased their target price on shares of Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating for the company in a research report on Friday, November 7th. Four research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $204.91.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.